Tracking pregnancy and baby health after hepatitis C treatment

This study is tracking pregnancies and baby health outcomes in women with hepatitis C who received direct-acting antiviral (DAA) medications—a newer type of hepatitis C treatment—during or shortly before pregnancy. Researchers want to understand whether treating hepatitis C during pregnancy is safe for both mother and baby, and whether it might reduce the chance of passing the infection to the newborn.

For years, women with hepatitis C during pregnancy couldn't safely receive treatment because older medications could harm the developing baby. The newer antiviral medications appear safer to use in pregnancy, and many women say they would want treatment if it could protect their baby from infection. However, doctors don't yet have clear information about how safe and effective this approach really is, so this registry is collecting real-world data to answer that question.